Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
News|Articles|August 31, 2026
August 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
Author(s)Leah Kuntz
Check out our pipeline updates from August!
Advertisement
Advertisement
Take a look at this month’s developments in the psychiatric treatment pipeline. We compiled a recap of the latest news here, just in case you missed any of the updates.
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Phase 3 BLOOM tests 48-hour at-home oral brexanolone for rapid postpartum depression relief, with tighter monitoring after prior trial issues.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.
Advertisement
Advertisement